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Paclitaxel plays an important role in the treatment of primary breast cancer. However, a substantial proportion of patients treated
with paclitaxel does not appear to derive any benefit from this therapy. We performed a prospective study using tumour cells
isolated from 50 primary breast carcinomas. Sensitivity of primary tumour cells to paclitaxel was determined in a clinically relevant
range of concentrations (0.85–27.2mgml
 1 paclitaxel) using an ATP assay. Chemosensitivity data were used to study a possible
association with immunohistochemically determined oestrogen and progesterone receptor (ER and PR) status, as well as
histopathological parameters. Progesterone receptor (PR) mRNA expression was also determined by quantitative RT–PCR. We
observed a clear association of the PR status with chemosensitivity to paclitaxel. Higher levels of immunohistochemically detected PR
expression correlated with decreased chemosensitivity (P¼0.008). Similarly, high levels of PR mRNA expression were associated
with decreased paclitaxel chemosensitivity (P¼0.007). Cells from carcinomas with T-stages 3 and 4 were less sensitive compared to
stages 1 and 2 (P¼0.013). Multiple regression analysis identified PR receptor status and T-stage as independent predictors of
paclitaxel chemosensitivity, whereas the ER, N-stage, grading and age were not influential. In conclusion, in vitro sensitivity to paclitaxel
was higher for PR-negative compared with PR-positive breast carcinoma cells. Thus, PR status should be considered as a possible
factor of influence when designing new trials and chemotherapy protocols.
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Taxanes like paclitaxel play an important role in the adjuvant
treatment of breast cancer (Henderson et al, 2003). The efficacy of
paclitaxel containing treatment can be further improved by dose
dense protocols in which the chemotherapy is administered every
2 weeks with G-CSF support. Arguably, sequential protocols in
which paclitaxel is administered not only dose dense, but also dose
intensified, might prove to be even more efficient. Despite the
well-documented antitumour efficacy of paclitaxel, many tumours
exhibit intrinsic resistance to paclitaxel. These patients will
obviously not profit from addition of paclitaxel to an anthra-
cycline-based adjuvant chemotherapy. Identifying these patients
could not only spare them an ineffective treatment, but gives the
opportunity to establish a more efficient protocol for this
particular subgroup of paclitaxel-resistant patients. In the adjuvant
setting, Henderson et al (2003) have shown that especially patients
whose tumours were oestrogen receptor (ER) negative derived
most of the benefit from adding paclitaxel to an anthracyclin-based
regimen. However, it is not entirely clear whether in this setting the
prognostic impact of the hormone receptor status and the effect
of adjuvant treatment with tamoxifen might thus offset a potential
predictive effect of the hormone receptor status for paclitaxel
chemosensitivity.
A large number of studies have been performed to identify
predictive markers for chemosensitivity and/or prognosis of
carcinomas (Hengstler et al, 1992, 2001; Micke et al, 2001, 2003;
Brenner et al, 2002; Hast et al, 2002; Schiffer et al, 2003; Steiner
et al, 2003; Mohrmann et al, 2005). Resistance to paclitaxel can
be induced by decreased expression of the spindle assembly
checkpoint genes Mad2 and BubR1 (Sudo et al, 2004). In contrast,
low expression of the microtubule-associated protein tau was
associated with high sensitivity to paclitaxel (Rouzier et al, 2005).
High expression of beta-tubulin III has been reported to predict
progression after paclitaxel chemotherapy (Paradiso et al, 2005).
Thus, genes involved in spindle assembly have a high probability
to be involved in paclitaxel resistance. This corresponds to the
mechanism of action, as paclitaxel stabilises microtubules.
Resistance to paclitaxel (Duan et al, 2005) and docetaxel (Chang
et al, 2003) has been reported to be associated with specific
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spatterns of gene expression. Interestingly, chemosensitivity of
primary tumour cells could be increased by inhibition of P-
glycoprotein (Di Nicolantonio et al, 2004). These examples
demonstrate that many factors that might predict paclitaxel
chemosensitivity of breast cancer patients have been discovered.
If validated, these factors could help to reduce unnecessary
treatment for women with breast cancer or help to identify
sensitive subpopulations. An important milestone in translation of
preclinical concepts to clinical application is the demonstration
that new predictive factors are independent from the classical
histopathological parameters. However, the influence of histo-
pathological factors, such as ER and PR status, T-stage, N-stage,
grading and patient’s age on paclitaxel chemosensitivity of the
breast carcinoma cells is still not clear. To clarify this controversial
issue, we performed a prospective study in 53 consecutive breast
cancer patients using an in vitro chemosensitivity assay (ATP-
TCA, Andreotti et al, 1995; Kurbacher et al, 1996; Hengstler et al,
1999b) with primary tumour cells isolated from resected breast
cancer tissue. Here, we report for the first time that PR status and
tumour stage are independent predictors of paclitaxel chemo-
sensitivity in primary breast cancer cells.
MATERIALS AND METHODS
Patients
We used fresh breast cancer tissue specimens of consecutive
patients who underwent surgery for primary breast cancer at the
Department of Obstetrics & Gynecology, University of Mainz,
Medical School during October 2002–September 2003. In this
period of time, 155 patients had surgery for primary breast cancer.
In 53 of these patients, a sufficient amount of fresh breast cancer
tissue (at least 0.5cm
3) allowed for in vitro chemosensitivity
testing. Patient characteristics are shown in Table 1.
In vitro chemosensitivity assay (ATP-TCA)
The chemosensitivity test was performed with primary tumour
cells that have been isolated from tumour tissue immediately after
resection. A commercially available kit (TCA-100; DCS, Innovative
Diagnostic Systeme, Hamburg, Germany) was used to assess
chemosensitivity according to the manufacturer’s instructions.
Briefly, tumour specimens were dispersed using sterile scalpels.
Subsequently, small tissue fragments were enzymatically disso-
ciated. After filtration and ficoll-hypaque density centrifugation,
the quality and viability of the single cell suspension were assessed
by trypan blue dye exclusion and cytological examination. Adding
serum-free Complete Assay Medium (CAM; DCS, Innovative
Diagnostic Systeme, Hamburg, Germany) cell suspensions were
adjusted to a final concentration of 1–2 10
5 viable cells per ml.
Assays for paclitaxel chemosensitivity were performed in 96-well
polypropylene microtitre plates. Test drug concentrations were
administered in triplicate in six different concentrations: 0.85, 1.7,
3.4, 6.8 and 13.6, 27.2mgml
 1 paclitaxel. Two controls were
included for analysis of each tumour, a negative control with
complete assay medium (M0) and a positive control containing
Maximum ATP Inhibitor (MI, Innovative Diagnostic Systeme,
Hamburg, Germany) instead of paclitaxel. Subsequently, 100mlo f
single cell suspension corresponding to 15000 cells were added to
each well. These cultures were then incubated at 371C and 95%
humidity in 5% CO2 atmosphere. After 6 days of incubation and a
cytological analysis of untreated controls, intracellular ATP was
extracted and stabilised by addition of 50ml tumour cell extraction
reagent (TCER; DCS, Innovative Diagnostic Systeme, Hamburg,
Germany) to the remaining wells of the culture plates. A 50ml
aliquot of each well was then transferred into a luminometer
(LB-953 luminometer, Berthold, Wildbad, Germany). After pipetting
50ml of luciferin–luciferase reagent (Lu-Lu; DCS, Innovative
Diagnostic Systeme, Hamburg, Germany) to each cell extract, the
ATP concentration was measured. An ATP standard curve was
included into all assays. Three independent incubations with
primary tumour cells of each patient were performed with all
paclitaxel concentrations (0.85, 1.7, 3.4, 6.8 and 13.6, 27.2mgml
 1),
and six independent incubations with the culture medium
controls. Median values for each concentration were used to
calculate the area under the curve (AUC). From a total of 53 tested
breast cancer specimens, three showed a too low ATP content of
the culture medium controls after a culture time of 6 days probably
owing to a too low viability of the isolated tumour cells. Therefore,
the overall evaluability rate was 94%.
Immunohistochemistry
Serial sections of formalin-fixed slices were stained with either
monoclonal ER antibodies (clone 1D5, Dako, Glostrup, Denmark)
or monoclonal PR antibodies (clone PgR 636, Dako, Glostrup,
Denmark), as described (Steiner et al, 2003). The immunohisto-
chemical evaluation was performed by one of the authors (MS)
trained in histological and immunohistochemical diagnostics,
unaware of the ATP-TCA data.
Quantitative RT–PCR for PRs A and B
Total RNA was isolated from 5mM sections of formalin-fixed,
paraffin-embedded tumour tissues after histopathological con-
firmation of a tumour cell content of at least 70%. Reverse
transriptase–polymerase chain reaction (RT–PCR) was performed
as described Hengstler et al (1999a). Primers and probes were
designed for both the exclusive detection of the PR-B isoform as
well as the simultaneous detection of the PR-A and PR-B isoforms
using the Primer Express software (Applied Biosystems, Foster
Table 1 Baseline characteristics of the study population
Number evaluated
(n¼50) % Not evaluable
Age (years) 59.2713.5
a
T-stage 1
T1 20 40.8
T2 20 40.8
T3 3 6.1
T4 6 12.2
N-stage 3
N0 20 42.6
N1 20 42.6
N2 2 4.3
N3 5 10.6
Grading 0
Grade 1 7 14.0
Grade 2 12 24.0
Grade 2 31 62.0
Histological type 1
Invasive ductal carcinoma 41 83.7
Other types 8 16.3
Estrogen receptor
b 0
Positive 35 70.0
Negative 15 30.0
Progesterone receptor
b 0
Positive 28 56.0
Negative 22 44.0
aMean7s.d.
bImmunohistochemically determined.
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sCity, CA, USA). Sequences of probe, forward and reverse primer
for (i) PGR (isoform B) and (ii) PGR (isoform AþB) were:
(i) Probe: 50 TCGCAGCAGGAGAAACTTGAAAGCATTC 30
Forward: 50 TCAAGAGGAGCAGGACATGTTG 30
Reverse: 50 TTCTCTCCCTTATGAGTTCCATAAAAG 30
(ii) Probe: 50 TTGATAGAAACGCTGTGAGCTCGA 30
Forward: 50 AGCTCATCAAGGCAATTGGTTT 30
Reverse: 50 ACAAGATCATGCAAGTTATCAAGAAGTT 30
To standardise the amount of sample RNA, GAPDH was selected
as a reference gene. Primer and probes were obtained from
Eurogentec s.a. (Liege, Belgium) and the sequences are shown
above.
Statistical analysis
The Statistical Package for Social Science (SPSS 12.0, Inc., Chicago,
IL, USA) was used for statistical analysis. Differences between AUC
values between two groups were evaluated using the t-test. Local
significance was considered as two-sided Po0.05. Linear regres-
sion analysis was used to model dependence of chemosensitivity
(AUC) on multiple covariates.
RESULTS
Paclitaxel chemosensitivity is associated with PR status
and tumour stage
For evaluation of paclitaxel chemosensitivity primary tumour cells
isolated from 50 breast cancer patients were analysed (baseline
characteristics: Table 1). The area under the dose–response curve
(AUC) was used as a measure for chemosensitivity. Representative
examples of a relatively sensitive and a relatively resistant tumour
as well as the frequency distribution of all AUCs are shown in
Figure 1. Next we analysed whether the AUC corresponds to the
progesterone and ER status (positive vs negative), as well as to T-
stage (stages 3 and 4 vs 1 and 2), N-stage (stages 1, 2, 3 vs 0),
grading (grade 3 vs 1 and 2) and age (older vs younger than 60
years) (Figure 2). A clear association was observed between PR
status and the AUC (P¼0.008), whereby a positive receptor status
was associated with decreased chemosensitivity (Figure 2). Simi-
larly, T-stage was associated with chemosensitivity to paclitaxel. T-
stage 3 and 4 carcinomas had lower AUCs compared with T-stage 1
and 2 (P¼0.013). In contrast, ER status, N-stage, grading and age
were not associated with chemosensitivity to paclitaxel (Figure 2).
Similar results were obtained when the IC90 was applied for
evaluation instead of the AUC (data not shown).
Multiple regression analysis identifies PR status and T-
stage as independent predictors of paclitaxel
chemosensitivity
To analyse which of the individual parameters shown in Figure 2
are independent predictors of paclitaxel chemosensitivity, we
performed a multiple linear regression analysis. Using a step down
approach, initially the PR status, T-stage, N-stage, grading and age
were included. The final model included only PR status (positive vs
negative, P¼0.015) and T-stage (stages 3 and 4 vs 1 and 2,
P¼0.021) as independent parameters of influence (P¼0.014).
PR-A and -B isoforms both are associated with paclitaxel
chemosensitivity
Next, we studied whether the correlation between paclitaxel
chemosensitivity and PR status could be confirmed on the mRNA
level. In accordance with previous studies we performed quanti-
tative RT–PCR using a primer pair specific for PR-B and another
primer pair amplifying both, PR-A and -B. High-quality RNA
could be isolated from only 46 of the 50 patients. mRNA
expression of PR-A and -B as well as of PR-B alone were
dichotomised using the respective medians as cutpoints. Both, PR-
A and -B as well as PR-B alone were associated with chemosensi-
tivity to paclitaxel (P¼0.007 and P¼0.022, respectively), whereby
tumours with relatively high levels of receptor expression appeared
less sensitive to paclitaxel compared with carcinomas with low
levels of the PR (Figure 3A and B). Thus, RT–PCR analysis
(Figure 3) confirmed the correlation between the immunohisto-
chemically (Figure 2A) determined PR expression and paclitaxel
chemosensitivity. The difference in chemosensitivity seems to be
slightly higher if PR-A and -B expression (Figure 3A) was
considered compared to PR-B alone (Figure 3B), suggesting that
PR-A might be more relevant than PR-B with respect to
chemosensitivity. However, owing to the relatively small difference
and owing to the fact that we did not specifically quantify PR-A,
conclusions as to possible differences between PR isoforms should
be treated with caution. In conclusion, the association of the PR
with paclitaxel chemosensitivity could be confirmed on the mRNA
level.
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Figure 1 (A) Representative results of the in vitro chemosensitivity assay.
Tumour no. 36 is relatively sensitive (AUC: 16.6) in contrast to tumour no.
2 (AUC: 9.5). A concentration of 3.7mgml
 1 paclitaxel corresponds to the
peak plasma concentration reached in patients. All data points are mean
values and standard deviations from three independent incubations. (B)
Frequency distribution of the AUCs of all 50 tumours.
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sInfluence of PR status and T-stage on paclitaxel dose—
response curves
To be able to quantitatively assess the association of PR status with
paclitaxel chemosensitivity we separately analysed tumour cells
from T-stage 1 or 2 as well as T-stage 3 or 4 patients. In the group
of T-stage 1 or 2 tumours a higher sensitivity was observed for the
PR-negative cells (Figure 4A). The difference in the AUC between
PR-negative and -positive cells in T-stage 1 or 2 was significant
(P¼0.027). A similar association between PR and sensitivity to
paclitaxel was seen in cells from T-stage 3 or 4 tumours (Figure 4B,
P¼0.049). The largest difference was obtained between PR-
negative/T-stage 1 or 2 vs PR-positive/T-stage 3 or 4 tumours
(Figure 4C, P¼0.001). In the concentration range between 1.7 and
3.4mgml
 1 approximately two-fold higher concentrations of
paclitaxel are required for PR positive/T-stage 3 or 4 tumours to
achieve a toxicity similar to that as for PR-negative/T-stage 1 or 2
tumours.
DISCUSSION
Selecting patients with primary breast cancer for the most
appropriate adjuvant systemic treatment is of great importance.
The only currently accepted and reliable predictive factor for
clinical decision making in the adjuvant setting is the hormone
receptor status (Goldhirsch et al, 2005). Besides hormone
receptors, there is no generally accepted factor for the prediction
of response to chemotherapy in breast cancer. HER-2/neu was
retrospectively investigated as a predictive factor for an anthra-
cycline-based therapy in comparison with CMF (Paik et al, 1998;
Moliterni et al, 2003). However, owing to inconsistent results,
HER-2/neu is currently not recommended in this setting (Gold-
hirsch et al, 2005). In an explorative subgroup analysis of the
randomised clinical trial CALGB 9344, Henderson et al (2003)
observed evidence that the ER status might be predictive for a
benefit of paclitaxel added to a standard anthracyclin-based
regimen. Patients with ER-positive tumours had a greater benefit
from the addition of paclitaxel to an anthracycline-based therapy
than patients with ER-negative tumours. However, based on this
finding, it is unclear whether this is truly predictive for paclitaxel
response or whether the well-known prognostic effects of the
hormone receptor status itself come into play. Other clinical trials
also investigated a possible interaction between the ER status and
paclitaxel (Mamounas et al, 2005) or docetaxel (Nabholtz et al,
2002). However, these trials failed to demonstrate any interaction
between clinical outcome and ER expression.
For the above mentioned reasons, the adjuvant setting is not
ideal to investigate the predictive effect of a biomarker. A design
which is much more appropriate for this particular purpose was
used in the National Surgical Adjuvant Breast and Bowel Project
Protocol (NSABP) B-27. In this clinical trial, patients with primary
breast cancer were treated with primary systemic chemotherapy
either with or without docetaxel. These authors again failed to
confirm any association between the ER status and the benefit
from the use of a taxane containing regimen. However, owing to
the concurrent administration of tamoxifen and chemotherapy, the
potential predictive effect of the ER for chemotherapy response
might be obscured.
In the present study, we excluded potential prognostic effects as
well as interference with other systemic therapies by using a well-
established in vitro assay (ATP-TCA) for primary tumour cells
(Andreotti et al, 1995; Cree et al, 1996; Kurbacher et al, 1996;
Hengstler et al, 1999b; Konecny et al, 2000) in a consecutive series
of 53 primary breast cancers. The ATP-TCA has been shown to
allow a prediction of clinical results. The ATP-TCA-directed
chemotherapy has improved clinical outcome in several studies
(Andreotti et al, 1995; Cree et al, 1996; Kurbacher et al, 1996;
Konecny et al, 2000). It should be considered that our ATP assay
measures chemosensitivity on a cellular level, which is only one of
several parameters relevant for clinical outcome. Other relevant
parameters, such as local pharmacokinetics, tumour vascularisa-
tion, oxygen supply or immune response will not be considered by
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Figure 2 Association between chemosensitivity to paclitaxel (expressed as AUC) and histopathological parameters. Only the progesterone receptor (PR)
status (P¼0.008) and T-stage (P¼0.013) correlated with chemosensitivity.
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sour in vitro technique. Nevertheless, the applied assay determines
whether tumour cells ex vivo dispose of mechanisms protecting
them from paclitaxel toxicity in vitro. This is likely to be one of
several parameters contributing to chemosensitivity of a tumour
in vivo. Our assay evaluability rate of 94% is well in line with the
literature (Cree et al, 1996; Kurbacher et al, 1996). The present
study was designed to study a possible association of ER and PR
status with chemosensitivity of breast cancer cells in the ATP-TCA
and to analyse whether a possible association is independent from
the classical clinical factors, such as T-stage, N-stage, grading and
age.
In the present prospective study, we observed a clear association
between the PR status and chemosensitivity to paclitaxel. Higher
levels of immunohistochemically detected PR expression corre-
lated with decreased chemosensitivity. To confirm this observation
by a second, independent technique, we measured PR expression
also by quantitative RT–PCR. Progesterone exerts its effects
through two nuclear receptors, PR-A and PR-B, which are encoded
by a single gene, under the regulation of two distinct promoters
(Kastner et al, 1990). The two receptor proteins are identical
except that PR-B contains an additional 164 amino acids at its
N-terminal end that are absent from PR-A. These two PR isoforms
can be distinguished by immunoblot analysis, but not by ligand-
binding assays or by immunohistochemistry. In accordance with
previous studies, we used two pairs of primers amplifying either a
fragment of the identical part (PR-A and -B) as well as a fragment
specific for PR-B. Similar to the result obtained by immunohis-
tochemistry, PR mRNA expression also correlated with chemo-
sensitivity. A high correlation of the two isoforms with each other
and also with total PR has been reported, indicating that virtually
every PR-positive breast tumour expresses at least some level of
PR-A and -B (Hopp et al, 2004). In our study, both, PR-A and -B
and PR-B mRNA expression correlated with decreased chemo-
sensitivity to paclitaxel.
We did not address the question of the molecular mechanisms
responsible for PR-mediated chemoresistance in the present study.
However, previous studies have demonstrated an up regulation
of the antiapoptotic gene BCL-XL in breast cancer cells as a
consequence of PR-A expression (Richer et al, 2002). This
upregulation could lead to resistance to apoptosis. As apoptosis
is a major factor for the cytotoxic effects exerted by paclitaxel
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s(Woods et al, 1995; Milross et al, 1996), it might explain why
PR-positive tumours were more resistant to paclitaxel compared
with PR-negative carcinomas. However, besides BCL-XL, at least
93 further genes have been shown to be PR-A and/ or PR-B
dependent in breast cancer cells (Richer et al, 2002). Therefore, it
can not be excluded that PR-mediated chemoresistance is multi-
factorial, whereby BCL-XL may represent only one of several
factors. Nevertheless, the antiapoptotic influence of the PR is well
documented. For instance, serum depletion-induced apoptosis was
inhibited by progesterone treatment (Ory et al, 2001) and also
radiation-induced apoptosis could be antagonised via PR (Vares
et al, 2004) in breast cancer cell lines.
Using multiple regression analysis we demonstrated that an
association of the PR with paclitaxel chemosensitivity is indepen-
dent from classical clinical prognostic factors. However, a second
factor was found to be influential, namely the T-stage. To be able
to quantitatively assess the association of PR status with T-stage,
we compared the dose–effect curves of four subgroups tumours:
(i) PR negative and T-stage 1 or 2, (ii) PR negative and T-stage 3 or
4, (iii) PR positive and T-stage 1 or 2 and (iv) PR positive and
T-stage 3 or 4. Tumours of PR-negative/T-stage 1 or 2 tumours
were clearly more sensitive than PR-positive/T-stage 3 or 4
tumours. The concentrations used in our in vitro study are 0,
0.85, 1.7, 3.4, 6.8 and 13.6, 27.2mgml
 1 paclitaxel. The choice of
these concentrations is based on pharmacokinetic data of a phase 3
randomised study following 3- and 24-h infusions of paclitaxel at
dose levels of 135 and 175mgm
 2. Maximum plasma concentra-
tions were 3.65mgml
 1 for 3h infusion of 175mgm
 2 paclitaxel.
Therefore, a clinically relevant dose range has been chosen in the
present study. In this range of clinically relevant concentrations,
approximately two-fold higher concentrations are required for
PR-positive/T-stage 3 or 4 tumours to achieve a similar toxicity
compared to PR-negative/T-stage 1 or 2 tumours. It is likely that
both PR and T-stage are only two of many factors influencing
paclitaxel sensitivity of breast cancer. Nevertheless, the results of
this study demonstrate that PR and T-stage should be considered
as influential parameters in studies aimed at identifying new
factors that might predict paclitaxel resistance.
In conclusion, our prospective study in primary breast cancer
highlights the importance of the PR for the chemosensitivity to
paclitaxel. Clearly, these ex vivo data should be taken as
hypothesis-generating results which have to be confirmed in
larger clinical trials.
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